Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

NCT01456351 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

230

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: Bendamustine plus Rituximab
DRUG: Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w

Sponsor

University of Giessen